The role of hdroxycarbamide in long term management of thalassemia intermedia patients / Esraa Abdelkader Elhosieny ; Supervised Amal Mohamed Ibrahim Elbeshlawy , Amina Abdelsalam Mahmoud , Hend Mehawed Abdelatef Soliman
Material type: TextLanguage: English Publication details: Cairo : Esraa Abdelkader Elhosieny , 2021Description: 121 P. : charts , facsimiles ; 25cmOther title:- دور هيدروكسى كارباميد فى علاج مرضى الثلاسيمية المتوسطه على المدى الطويل [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.28.M.Sc.2021.Es.R (Browse shelf(Opens below)) | Not for loan | 01010110084908000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.28.M.Sc.2021.Es.R (Browse shelf(Opens below)) | 84908.CD | Not for loan | 01020110084908000 |
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
In thalassemia intermedia, there is incomplete inhibition of beta globin protein production. Hydroxyurea increases level of gamma globin and may be effective in these patients.This study was done to evaluate the effect of hydroxyurea in clinical and laboratory profile of these patients. Most of TI patients were female (95.6%), with prevalence of disease related complications about 91.1%. hydroxyurea was well tolerated in 66.6% of patients, and 11.1% had side effects in the form of neutropenia, and elevated liver enzymes. Frequency of blood transfusion was significantly decreased after use of HU. Hb, MCV, MCH, HbF and bleeding profile showed significant increase after HU.There was statistically significant decrease of serum Ferritin, direct bilirubin after HU treatment
Issued also as CD
There are no comments on this title.